{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:20Z","timestamp":1792099580296,"version":"4.4.0"},"reference-count":72,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is a rare B\u2010cell non\u2010Hodgkin lymphoma (NHL) that is aggressive and incurable with existing therapies, presenting a significant unmet clinical need. MCL occurs mainly in elderly patients with comorbidities; thus, intense treatment options including allogeneic stem cell transplantation (Allo\u2010SCT) are not feasible. New treatment options are emerging for this elderly\/unfit treatment group, we therefore conducted a systematic review to determine whether they offered an advance on the existing recommended treatment, R\u2010CHOP. The search strategies to identify MCL therapies were designed to capture the most relevant studies from 2013 to 2020. Following preferred reporting items for systematic reviews and meta\u2010analyses and population,interventions, observations and study design analysis, R\u2010CHOP, ibrutinib and bendamustine plus rituximab (BR) were taken forward for critical and statistical analysis. All three therapies were effective in increasing the overall survival (OS) and progression\u2010free survival of elderly\/unfit patients with MCL. However, none resulted in a significant increase in OS compared to R\u2010CHOP. In addition, R\u2010CHOP had a better toxicity profile when compared to both ibrutinib and BR. We therefore conclude that treatment of elderly\/unfit patients with MCL is still a significant unmet clinical need; and suggest that outside of the clinical trial setting, R\u2010CHOP should remain the recommended front\u2010line treatment for this patient group.<\/jats:p>","DOI":"10.1002\/jha2.311","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T09:46:31Z","timestamp":1636451191000},"page":"276-290","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mantle cell lymphoma treatment options for elderly\/unfit patients: A systematic review"],"prefix":"10.1002","volume":"3","author":[{"given":"Tahera","family":"Alnassfan","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Cancer Medicine University of Liverpool  Liverpool UK"},{"name":"Authors Tahera Alnassfan and Megan J. Cox\u2010Pridmore contributed equally to the review"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan J.","family":"Cox\u2010Pridmore","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Cancer Medicine University of Liverpool  Liverpool UK"},{"name":"Authors Tahera Alnassfan and Megan J. Cox\u2010Pridmore contributed equally to the review"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzam","family":"Taktak","sequence":"additional","affiliation":[{"name":"Medical Physics and Clinical Engineering Royal Liverpool University Hospital  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-5771","authenticated-orcid":false,"given":"Kathleen J","family":"Till","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Cancer Medicine University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-019-0126-0"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5904"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15108"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010264"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14122.1"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds643"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1155\/2001\/28962"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14920"},{"key":"e_1_2_10_12_1","unstructured":"FDA. FDA grants accelerated approval to acalabrutinib for mantle cell lymphoma.2017."},{"key":"e_1_2_10_13_1","unstructured":"FDA. FDA grants accelerated approval to zanubrutinib for mantle cell lymphoma.2019."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00665"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3041"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051328"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00914-1"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.6.8.1175"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0010"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15108"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.3049.3049"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16257"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2565"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0871"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2225"},{"key":"e_1_2_10_28_1","first-page":"148","article-title":"Impact of rituximab (rituxan) on the treatment of B\u2010cell non\u2010Hodgkin's lymphoma","volume":"35","author":"Dotan E","year":"2010","journal-title":"Pharmacy Ther."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.15190\/d.2014.6"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.534518"},{"key":"e_1_2_10_31_1","unstructured":"CancerNetwork. Rituxan plus CHOP approved for diffuse large B\u2010cell lymphoma. Vol.2021.2006."},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30685-5"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.10.006"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002068"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.21037\/aol.2019.06.02"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2004.05.009"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1196-5"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.191619"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229170"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.5.1644"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e01297"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801327"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2596"},{"key":"e_1_2_10_45_1","unstructured":"NICE. Bendamustine in combination with rituximab for the first\u2010line treatment of mantle cell lymphoma.2012"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1317-x"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2011.03.003"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0621-5"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1512455"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.181"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.591577"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-015-0004-3"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-791392"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25215"},{"key":"e_1_2_10_56_1","first-page":"4583","article-title":"Mantle cell lymphoma: a North Indian Tertiary Care Centre Experience","volume":"17","author":"Das Ch K","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2014.49.1.15"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01294"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110520"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.016"},{"key":"e_1_2_10_61_1","first-page":"2084","article-title":"Mantle cell lymphoma: a Turkish Multi\u2010Center Study","volume":"24","author":"Okay M","year":"2019","journal-title":"J BUON"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49776-9"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.128710"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16922"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15170"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.152496"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5"},{"key":"e_1_2_10_68_1","unstructured":"DavisS TappendenP CantrellA. A review of studies examining the relationship between progression\u2010free survival and overall survival in advanced or metastatic cancer. London: NICE;2012"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620715592569"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0098"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17363"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879429"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17513"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.311","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.311","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T15:23:32Z","timestamp":1693236212000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/jha2.311"],"URL":"https:\/\/doi.org\/10.1002\/jha2.311","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]},"assertion":[{"value":"2021-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}